Recurrent acute pancreatitis prevention by the elimination of alcohol and cigarette smoking (REAPPEAR): protocol of a randomised controlled trial and a cohort study


Por: Ocskay, K, Juhasz, M, Farkas, N, Zadori, N, Szako, L, Szakacs, Z, Szentesi, A, Eross, B, Miklos, E, Zemplenyi, A, Birkas, B, Csatho, A, Hartung, I, Nagy, T, Czopf, L, Izbeki, F, Gajdan, L, Papp, M, Czako, L, Illes, D, Marino, M, Mirabella, A, Malecka-Panas, E, Zatorski, H, Susak, Y, Opalchuk, K, Capurso, G, Apadula, L, Gheorghe, C, Saizu, I, Petersen, O, De-Madaria, E, Rosendahl, J, Parniczky, A, Hegyi, P and Hungarian Pancreatic Study Grp

Publicada: 1 ene 2022 Ahead of Print: 4 ene 2022
Resumen:
Background/objectives Acute recurrent pancreatitis (ARP) due to alcohol and/or tobacco abuse is a preventable disease which lowers quality of life and can lead to chronic pancreatitis. The REAPPEAR study aims to investigate whether a combined patient education and cessation programme for smoking and alcohol prevents ARP. Methods and analysis The REAPPEAR study consists of an international multicentre randomised controlled trial (REAPPEAR-T) testing the efficacy of a cessation programme on alcohol and smoking and a prospective cohort study (REAPPEAR-C) assessing the effects of change in alcohol consumption and smoking (irrespective of intervention). Daily smoker patients hospitalised with alcohol-induced acute pancreatitis (AP) will be enrolled. All patients will receive a standard intervention priorly to encourage alcohol and smoking cessation. Participants will be subjected to laboratory testing, measurement of blood pressure and body mass index and will provide blood, hair and urine samples for later biomarker analysis. Addiction, motivation to change, socioeconomic status and quality of life will be evaluated with questionnaires. In the trial, patients will be randomised either to the cessation programme with 3-monthly visits or to the control group with annual visits. Participants of the cessation programme will receive a brief intervention at every visit with direct feedback on their alcohol consumption based on laboratory results. The primary endpoint will be the composite of 2-year all-cause recurrence rate of AP and/or 2-year all-cause mortality. The cost-effectiveness of the cessation programme will be evaluated. An estimated 182 participants will be enrolled per group to the REAPPEAR-T with further enrolment to the cohort. Ethics and dissemination The study was approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (40394-10/2020/EuIG), all local ethical approvals are in place. Results will be disseminated at conferences and in peer-reviewed journals.

Filiaciones:
Ocskay, K:
 Univ Pecs, Szentagothai Res Ctr, Med Sch, Inst Translat Med, Pecs, Hungary

 Semmelweis Univ, Ctr Translat Med, Budapest, Hungary

Juhasz, M:
 Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary

Farkas, N:
 Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary

 Univ Pecs, Med Sch, Inst Bioanal, Pecs, Hungary

Zadori, N:
 Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary

Szako, L:
 Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary

Szakacs, Z:
 Univ Pecs, Szentagothai Res Ctr, Med Sch, Inst Translat Med, Pecs, Hungary

Szentesi, A:
 Univ Pecs, Szentagothai Res Ctr, Med Sch, Inst Translat Med, Pecs, Hungary

Eross, B:
 Univ Pecs, Szentagothai Res Ctr, Med Sch, Inst Translat Med, Pecs, Hungary

 Semmelweis Univ, Ctr Translat Med, Budapest, Hungary

Miklos, E:
 Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary

Zemplenyi, A:
 Univ Pecs, Fac Pharm, Div Pharmacoecon, Pecs, Hungary

 Univ Pecs, Ctr Hlth Technol Assessment, Pecs, Hungary

Birkas, B:
 Univ Pecs, Med Sch, Inst Behav Sci, Pecs, Hungary

Csatho, A:
 Univ Pecs, Med Sch, Inst Behav Sci, Pecs, Hungary

Hartung, I:
 Univ Pecs, Med Sch, Inst Behav Sci, Pecs, Hungary

Nagy, T:
 Univ Pecs, Med Sch, Dept Lab Med, Pecs, Hungary

Czopf, L:
 Univ Pecs, Med Sch, Dept Med 1, Div Cardiol & Angiol, Pecs, Hungary

Izbeki, F:
 Szent Gyorgy Univ Teaching Hosp Fejer Cty, Dept Internal Med 1, Szekesfehervar, Hungary

Gajdan, L:
 Szent Gyorgy Univ Teaching Hosp Fejer Cty, Dept Internal Med 1, Szekesfehervar, Hungary

Papp, M:
 Univ Debrecen, Dept Internal Med, Div Gastroenterol, Debrecen, Hungary

Czako, L:
 Univ Szeged, Fac Med, Dept Med 1, Szeged, Hungary

Illes, D:
 Univ Szeged, Fac Med, Dept Med 1, Szeged, Hungary

Marino, M:
 Azienda Osped Osped Riuniti Villa Sofia Cervello, Gen & Emergency Surg Dept, Palermo, Italy

Mirabella, A:
 Azienda Osped Osped Riuniti Villa Sofia Cervello, Gen & Emergency Surg Dept, Palermo, Italy

Malecka-Panas, E:
 Med Univ Lodz, Dept Digest Tract Dis, Lodz, Poland

Zatorski, H:
 Med Univ Lodz, Dept Digest Tract Dis, Lodz, Poland

Susak, Y:
 Bogomolets Natl Med Univ, Dept Surg, Kiev, Ukraine

Opalchuk, K:
 Bogomolets Natl Med Univ, Dept Surg, Kiev, Ukraine

Capurso, G:
 Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Pancreas Translat & Clin Res Ctr, Milan, Italy

Apadula, L:
 Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Pancreas Translat & Clin Res Ctr, Milan, Italy

Gheorghe, C:
 Clin Inst Fundeni, Bucharest, Romania

 Carol Davila Univ Med & Pharm, Bucharest, Romania

Saizu, I:
 Clin Inst Fundeni, Bucharest, Romania

 Carol Davila Univ Med & Pharm, Bucharest, Romania

Petersen, O:
 Cardiff Univ, Cardiff, Wales

:
 Alicante Univ Gen Hosp, Alicante Inst Hlth & Biomed Res ISABIAL, Gastroenterol Dept, Alicante, Spain

Rosendahl, J:
 Martin Luther Univ Halle Wittenberg, Dept Internal Med 1, Halle, Germany

Parniczky, A:
 Univ Pecs, Med Sch, Inst Translat Med, Pecs, Hungary

 Heim Pal Natl Pediat Inst, Budapest, Hungary

Hegyi, P:
 Univ Pecs, Szentagothai Res Ctr, Med Sch, Inst Translat Med, Pecs, Hungary

 Semmelweis Univ, Ctr Translat Med, Budapest, Hungary
ISSN: 20446055





BMJ Open
Editorial
BMJ PUBLISHING GROUP, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 12 Número: 1
Páginas:
WOS Id: 000739490700018
ID de PubMed: 34983758
imagen gold, Green Accepted

MÉTRICAS